Cost-effectiveness of a new interferon-based blood assay, QuantiFERON®-TB Gold, in screening tuberculosis contacts

International Journal of Tuberculosis and Lung Disease

Volumn 12, Issue 12, 2008, Pages 1414-1424

  Marra, F ^a,b   Marra, Carlo A ^a,c   Sadatsafavi, M ^a   Moran Mendoza O ^d,e   Cook, V ^a,b   Elwood, R K ^a,b   Morshed, M ^a,b   Brunham, R C ^a,b   FitzGerald, J M ^a,f  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BRITISH COLUMBIA CENTRE FOR DISEASE CONTROL   (Canada)

^c CENTRE FOR HEALTH EVALUATION AND OUTCOME SCIENCES   (Canada)

^d QUEEN S UNIVERSITY   (Canada)

^e UNIVERSIDAD AUTÓNOMA DE SAN LUIS POTOSÍ   (Mexico)

^f VANCOUVER COASTAL HEALTH RESEARCH INSTITUTE   (Canada)

Author keywords

Contacts; Cost effectiveness analysis; Interferon gamma release assays; QuantiFERON TB Gold; Tuberculosis

Indexed keywords

INTERFERON;

ADULT; ARTICLE; BCG VACCINATION; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC KIT; DIAGNOSTIC TEST; ETHNICITY; HUMAN; INTERMETHOD COMPARISON; LUNG TUBERCULOSIS; PRIORITY JOURNAL; SCREENING TEST; SENSITIVITY AND SPECIFICITY; TUBERCULIN TEST;

ADOLESCENT; ADULT; BCG VACCINE; CANADA; CONTACT TRACING; COST-BENEFIT ANALYSIS; HUMANS; INTERFERON-GAMMA; LABORATORY TECHNIQUES AND PROCEDURES; MARKOV CHAINS; MIDDLE AGED; SENSITIVITY AND SPECIFICITY; TUBERCULIN TEST; TUBERCULOSIS; VACCINATION;

EID: 58049190874     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: controlling tuberculosis in the United States. Am J Respir Crit Care Med 2005; 172: 1169-227.
2. Farhat M, Greenaway C, Pai M, Menzies D. False-positive tuberculin skin tests: what is the absolute effect of BCG and non-tuberculous mycobacteria? Int J Tuberc Lung Dis 2006; 10: 1192-1204.
3. Menzies D. What does tuberculin reactivity after bacille Calmette-Guérin vaccination tell us? Clin Infect Dis 2000; 31 (Suppl 3): S71-S74.
4. Menzies D. Interpretation of repeated tuberculin tests. Boosting, conversion and reversion. Am J Respir Crit Care Med 1999; 159: 15-21.
5. Mori T, Sakatani M, Yamagishi F, et al. Specific detection of tuberculosis infection: an interferon-gamma-based assay using new antigens. Am J Respir Crit Care Med 2004; 170: 59-64.
6. Pai M, Kalantri S, Dheda K. New tools and emerging technologies for the diagnosis of tuberculosis: part I. Latent tuberculosis. Expert Rev Mol Diagn 2006; 6: 413-422.
7. Marks S M, Taylor Z, Quails N L, Shrestha-Kuwahara R J, Wilce M A, Nguyen C H. Outcomes of contact investigations of infectious tuberculosis patients. Am J Respir Crit Care Med 2000; 162: 2033-2038.
8. Ferrara G, Losi M, D'Amico R, et al. Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study. Lancet 2006; 367: 1328-1334.
9. Horsburgh C R Jr. Priorities for the treatment of latent tuberculosis infection in the United States. N Engl J Med 2004; 350: 2060-2067.
10. Guidelines for the investigation of contacts of persons with infectious tuberculosis. Recommendations from the National Tuberculosis Controllers Association and CDC. MMWR Recomm Rep 2005; 54 (RR-15): 1-47.
11. Colditz G A, Brewer T F, Berkey C S, et al. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 1994; 271: 698-702.
12. Comstock G W. How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults? Int J Tuberc Lung Dis 1999; 3: 847-850.
13. Khan K, Muennig P, Behta M, Zivin J G. Global drug-resistance patterns and the management of latent tuberculosis infection in immigrants to the United States. N Engl J Med 2002; 347: 1850-1859.
14. Borgdorff M W, Behr M A, Nagelkerke N J, Hopewell P C, Small P M. Transmission of tuberculosis in San Francisco and its association with immigration and ethnicity. Int J Tuberc Lung Dis 2000; 4: 287-294.
15. Schwartzman K, Menzies D. Tuberculosis screening of immigrants to low-prevalence countries. A cost-effectiveness analysis. Am J Respir Crit Care Med 2000; 161: 780-789.
16. Salpeter S R. Fatal isoniazid-induced hepatitis. Its risk during chemoprophylaxis. West J Med 1993; 159: 560-564.
17. Millard P S, Wilcosky T C, Reade-Christopher S J, Weber D J. Isoniazid-related fatal hepatitis. West J Med 1996; 164: 486-491.
18. Brown R E, Miller B, Taylor W R, et al. Health-care expenditures for tuberculosis in the United States. Arch Intern Med 1995; 155: 1595-1600.
19. Long R, Njoo H, Hershfield E. Tuberculosis: 3. Epidemiology of the disease in Canada. CMAJ 1999; 160: 1185-1190.
20. Duchesne D. Complete life table, Canada, 2000-2002. Catalogue no. 84-537-XIE. Ottawa, Canada: Statistics Canada Health Statistics Division, 2002. www.statcan.ca/english/freepub/84-537-XIE/tables.htm Accessed September 2008.
21. Grzybowski S, Barnett G D, Styblo K. Contacts of cases of active pulmonary tuberculosis. Bull Int Union Tuberc 1975; 50 (1): 90-106.
22. van Geuns H A, Meijer J, Styblo K. Results of contact examination in Rotterdam, 1967-1969. Bull Int Union Tuberc 1975; 50 (1): 107-121.
23. Karalus N C. Contact screening procedures for tuberculosis in Auckland. N Z Med J 1988; 101: 45-49.
24. Greenaway C, Palayew M, Menzies D. Yield of casual contact investigation by the hour. Int J Tuberc Lung Dis 2003; 7 (Suppl 3): S479-S485.
25. Public Health Agency of Canada. Canadian Tuberculosis Standards. 5th ed Ottawa, Canada: PHAC, 2000.
26. Mazurek G H, Jereb J, Lobue P, Iademarco M F, Metchock B, Vernon A. Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR Recomm Rep 2005; 54 (RR 15): 49-55.
27. National Collaborating Centre for Chronic Conditions. Tuberculosis: clinical diagnosis and management of tuberculosis, and measures for its prevention and control. London, UK: Royal College of Physicians, 2006.
28. Arend S M, Thijsen S F T, Leyten E M S, et al. Comparison of two interferon-gamma assays and tuberculin skin test for tracing tuberculosis contacts. Am J Respir Crit Care Med 2007; 175: 618-627.
29. Cauthen G M, Snider D E Jr, Onorato I M. Boosting of tuberculin sensitivity among South-east Asian refugees. Am J Respir Crit Care Med 1994; 149: 1597-1600.
30. Menzies D, Pai M, Comstock G. Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Ann Intern Med 2007; 146: 340-354.
31. Lee J Y, Choi H J, Park I N, et al. Comparison of two commercial interferon-gamma assays for diagnosing Mycobacterium tuberculosis infection. Eur Respir J 2006; 28: 24-30.
32. Dewan P K, Grinsdale J, Liska S, Wong E, Fallstad R, Kawamura L M. Feasibility, acceptability, and cost of tuberculosis testing by whole-blood interferon-gamma assay. BMC Infect Dis 2006; 6: 47.
33. Ferebee S H. Controlled chemoprophylaxis trials in tuberculosis. A general review. Bibl Tuberc 1970; 26: 28-106.
34. British Columbia Center for Disease Control. TB annual report. Vancouver, BC, Canada: BCCDC, 2004. http://www.bccdc.org/downloads/pdf/tb/reports/ 2004_TB_Annual.pdf Accessed September 2008.
35. Sutherland I. Recent studies in the epidemiology of tuberculosis, based on the risk of being infected with tubercle bacilli. Adv Tuberc Res 1976; 19: 1-63.
36. Borgdorff M W, Nagelkerke N J, van Soolingen D, Broekmans J F. Transmission of tuberculosis between people of different ages in The Netherlands: an analysis using DNA fingerprinting. Int J Tuberc Lung Dis 1999; 3: 202-206.
37. Blumberg H M, Burman W J, Chaisson R E, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003; 167: 603-662.
38. Medical Service Plan (MSP). Medical Services Commission, payment schedule. Vancouver, BC, Canada: Ministry of Health, Government of British Columbia, 2007. http://www.health.gov.bc.ca/msp/infoprac/physbilling/ payschedule/pdf/7.%20general_practice.pdf Accessed June 2008.
39. Oxlade O, Schwartzman K, Menzies D. Interferon-gamma release assays and TB screening in high-income countries: a cost-effectiveness analysis. Int J Tuberc Lung Dis 2007; 11: 16-26.
40. Dasgupta K, Menzies D. Cost-effectiveness of tuberculosis control strategies among immigrants and refugees. Eur Respir J 2005; 25: 1107-1116.
41. Bank of Canada. Consumer Price Index, 1995 to present. Ottawa, ON, Canada: Bank of Canada, 2007. http://www.bankofcanada.ca/en/cpi.html Accessed June 2008.
42. Guo N, Marra C A, Marra F, Moadebi S, Elwood R K, Fitzgerald J M. Health state utilities in latent and active tuberculosis. Value Health 2008 May 16. [epub ahead of print]
43. Longworth L, Bryan S. An empirical comparison of EQ-5D and SF-6D in liver transplant patients. Health Econ 2003; 12: 1061-1067.
44. Hoch J S, Briggs A H, Willan A R. Something old, something new, something borrowed, something blue: a framework for the marriage of health econometrics and cost-effectiveness analysis. Health Econ 2002; 11: 415-430.
45. Drummond M F S M, Torrance G W, O'Brien B J, Stoddart G L. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford, UK: Oxford Medical Publications, 2005.
46. Diel R, Nienhaus A, Loddenkemper R. Cost-effectiveness of interferon-gamma release assay screening for latent tuberculosis infection treatment in Germany. Chest 2007; 131: 1424-1434.
47. FitzGerald J M, Wang L, Elwood R K. Tuberculosis: 13. Control of the disease among aboriginal people in Canada. CMAJ 2000; 162: 351-355.
48. Woldehanna S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev 2004(1): CD000171.
49. Rangaka M X, Wilkinson K A, Seldon R, et al. Effect of HIV-1 infection on T-cell-based and skin test detection of tuberculosis infection. Am J Respir Crit Care Med 2007; 175: 514-520.